Table 1.
Training set, internal validation set, NASH CRN cohort and French NAFLD cohort patient characteristics.
| Training set n = 1,434 |
Internal VS n = 700 |
NASH CRN cohort n = 585 |
French NAFLD cohort* n = 1,042 |
|||||
|---|---|---|---|---|---|---|---|---|
| Median (IQR) or n (%) |
N | Median (IQR) or n (%) |
N | Median (IQR) or n (%) |
N | Median (IQR) or n (%) |
N | |
| Demographics | ||||||||
| Age (years) | 55.0 (16.0) | 1,434 | 55.5 (16.0) | 700 | 54.0 (17.0) | 585 | 58.0 (15.4) | 1,042 |
| Male sex | 729 (50.8%) | 1,434 | 359 (51.3%) | 700 | 219 (37.4%) | 585 | 622 (59.7%) | 1,042 |
| BMI (kg/m2) | 31.7 (7.80) | 1,325 | 31.6 (8.05) | 646 | 34.6 (9.10) | 584 | 31.2 (7.7) | 1,037 |
|
| ||||||||
| Metabolic | ||||||||
| Diabetes (type 1 and 2) | 723 (50.4%) | 1,434 | 357 (51.0%) | 700 | 268 (45.8%) | 585 | 508 (48.8%) | 1,042 |
| Hypertension | 719 (50.1%) | 1,434 | 344 (49.1%) | 700 | 334 (57.1%) | 585 | – | –** |
|
| ||||||||
| Blood | ||||||||
| AST (U/L) | 39.0 (31.0) | 1,434 | 38.0 (29.0) | 700 | 37.0 (28.0) | 585 | 39.5 (26.0) | 1,042 |
| ALT (U/L) | 49.0 (47.0) | 1,434 | 47.0 (45.2) | 700 | 48.0 (42.0) | 585 | 57.0 (45.0) | 1,042 |
| AAR | 0.808 (0.381) | 1,434 | 0.820 (0.397) | 700 | 0.793 (0.332) | 585 | 0.72 (0.37) | 1,042 |
| Platelets count (G/L) | 219 (94.0) | 1,434 | 222 (95.2) | 700 | 228 (92.0) | 585 | 218 (85.0) | 1,042 |
| HDL (mmol/L) | 1.14 (0.414) | 1,114 | 1.11 (0.390) | 541 | 1.11 (0.388) | 581 | 1.14 (0.390) | 997 |
| LDL (mmol/L) | 2.59 (1.32) | 1,088 | 2.56 (1.24) | 530 | 2.61 (1.33) | 568 | – | –*** |
| Albumin (g/L) | 45.0 (5.00) | 1,338 | 44.0 (5.00) | 654 | 44.0 (4.00) | 583 | 43.0 (5.0) | 1,033 |
| GGT (IU/L) | 58.0 (70.0) | 1,337 | 61.0 (71.8) | 654 | 43.0 (53.0) | 581 | 77.5 (106.3) | 1,042 |
| Triglycerides (mmol/L) | 1.69 (1.04) | 1,119 | 1.64 (1.03) | 545 | 1.62 (1.11) | 581 | 1.53 (1.03) | 1,002 |
| Fasting glucose (mmol/L) | 6.11 (2.36) | 1,315 | 6.10 (2.39) | 645 | 5.88 (1.94) | 582 | 5.80 (2.30) | 1,011 |
|
| ||||||||
| Non-invasive tests | ||||||||
| FIB-4 | 1.40 (1.25) | 1,434 | 1.40 (1.20) | 700 | 1.30 (1.06) | 585 | 1.40 (1.17) | 1,042 |
| LSM by VCTE (kPa) | 10.8 (10.2) | 1,434 | 10.5 (9.83) | 700 | 8.60 (7.20) | 585 | 8.50 (6.70) | 1,042 |
|
| ||||||||
| Fibrosis stage | ||||||||
| NASH CRN scoring system | 1,434 | 700 | 585 | 1,042 | ||||
| F0 | 202 (14.1%) | 97 (13.9%) | 121 (20.7%) | 116(11.1%) | ||||
| F1 | 269 (18.8%) | 130 (18.6%) | 134 (22.9%) | 240 (23.0%) | ||||
| F2 | 191 (13.3%) | 93 (13.3%) | 116 (19.8%) | 286 (27.5%) | ||||
| F3 | 437 (30.5%) | 215 (30.7%) | 139 (23.8%) | 267 (25.6%) | ||||
| F4 | 335 (23.4%) | 165 (23.6%) | 75 (12.8%) | 133 (12.8%) | ||||
AAR, AST/ALT ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FIB-4, Fibrosis-4 index; GGT, gamma-glutamyltransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LSM, liver stiffness measurement; NAFLD, non-alcoholic fatty liver disease; NASH CRN, Non-alcoholic Steatohepatitis Clinical Research Network; VCTE, vibration-controlled transient elastography; VS, validation set.
*
Analysis performed by Professor Boursier and his team.
**
22% missing data.
***
51% missing data. Results are median (IQR) and number of available data for numeric parameters and n (%) for categorical parameters.